Product Sales was Maxcyte’s largest product and service line in fiscal 2025, bringing in $18.69M of $20.96M (89%).
| Product and Service | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|
| Product Sales | $27.73M | $18.60M | $18.69M | ||
| Assay & Other Service Revenue | — | — | $1.97M | ||
| Other | $1.02M | $897.00K | — | ||
| Licenses | — | — | $300.00K | ||
| Total | $28.75M | $19.50M | $20.96M |
Maxcyte brought in $20.96M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Maxcyte regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $19.50M. Product Sales was the largest at $18.69M (89.2%), ahead of Assay & Other Service Revenue at $1.97M (9.4%) and Licenses at $300.00K (1.4%).
Maxcyte began breaking out Assay & Other Service Revenue in fiscal 2025 and Licenses in fiscal 2025. Maxcyte stopped reporting Other as a separate line after fiscal 2023, when it brought in $897.00K.
Inside The United States was Maxcyte’s largest region in fiscal 2024, bringing in $25.77M of $38.63M (67%).
| Geography | FY 2024 |
|---|---|
| Inside The United States | $25.77M |
| Outside The United States | $12.86M |
| Total | $38.63M |
Maxcyte brought in $38.63M from its two regions in fiscal 2024, the year ended December 31, 2024. Inside The United States was the largest at $25.77M (66.7%), ahead of Outside The United States at $12.86M (33.3%).
Maxcyte (MXCT) reports its revenue by product and service and by geography. In fiscal 2025, Product Sales was its largest product and service line, bringing in $18.69M (89.2% of the total), followed by Assay & Other Service Revenue at $1.97M (9.4%).
Product Sales was Maxcyte's largest product and service line in fiscal 2025, bringing in $18.69M, or 89.2% of the $20.96M total across its three product and service lines.
Inside The United States was Maxcyte's largest region in fiscal 2024, bringing in $25.77M, or 66.7% of the $38.63M total across its two regions.
Every figure comes from Maxcyte's annual financial filings, as reported. Each line keeps the name Maxcyte gives it, and years follow its fiscal calendar.
Maxcyte's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.